1. Introduction {#s0005}
===============

Alzheimer׳s disease (AD) is the most common type of dementia among older people, affecting approximately 35 million people worldwide, with 5 million new cases every year[@bib1]. Clinical symptoms of AD include progressive cognitive decline, irreversible memory loss, disorientation, language impairment, and emotional instability[@bib1]. The dilemma places significant mental, social and economic burdens on patients, families, and communities[@bib1]. Unfortunately, there are no currently effective treatments available to reverse or stop the progress of this devastating disease, primarily due to difficulties in identification of disease etiology[@bib2], [@bib3], [@bib4].

Several pathological hallmarks of this disease have been identified, namely, the deposition of amyloid-*β* (A*β*) plaques and neurofibrillary tangles, elevated reactive oxygen species (ROS), imbalanced metal ion (*e.g*., Cu, Fe, and Zn) homeostasis, and decreased brain acetylcholine (Ach) levels. Three major theories have been proposed to explain these pathological hallmarks: amyloid cascade[@bib3], [@bib5], [@bib6], oxidative stress[@bib7], [@bib8], and the metal ion hypotheses[@bib7]. The amyloid cascade hypothesis is currently the prevailing one. It is believed that the formation A*β* plaques arises from aggregation of peptides A*β*~40~ and A*β*~42~, and is the initial event in the pathogenesis of the AD. A*β*~40~ and A*β*~42~ are degradation products of amyloid peptide precursor (APP), generated from cleavage by *β*- and *γ*-secretases. These cleaved peptides have a tendency to aggregate into different A*β* species such as dimers, oligomers, fibrils, and plaques, and may also interact with metal ions and produce ROS, with subsequent neuronal atrophy and death[@bib4]. Regardless of the nature of the intertwined toxicological pathways induced by A*β* aggregates, it is widely accepted that the formation of A*β* plaques precedes the clinical symptoms of AD. Therefore, they are excellent diagnostic and predictive biomarkers for the early detection of AD[@bib5], [@bib6], [@bib9]. Moreover, the current clinical diagnosis of AD is primarily based upon family and patient׳s medical history as well as neurological and neuropsychological observations. Thus, the diagnosis is often inaccurate. Confirmative AD diagnosis can only be made through postmortem histopathological examination of brain A*β* plaques. There exists a great and urgent need to develop non-invasive and accurate probes for A*β* plaques to improve the current diagnosis of AD. Such probes will also be useful in monitoring disease progression and effectiveness of new AD treatments.

In the past decade, significant advances have been made in the design of molecular probes for specific labeling, detection, imaging of A*β* plaques both *in vitro* and *in vivo*. A number of different imaging modalities and approaches have been applied, including magnetic resonance imaging (MRI)[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], positron emission tomography (PET)[@bib15], [@bib16], [@bib17], [@bib18], [@bib19], single photon emission computed tomography (SPECT)[@bib20], [@bib21], [@bib22], [@bib23], [@bib24], and optical imaging techniques[@bib25]. MRI based approaches suffer from low resolution since the size of A*β* plaques typically range from 20 to 60 μm, while only larger plaques (\>50 μm) are detectable[@bib26]. Compared with MRI, radio-labeled PET and SPECT probes are more sensitive methods. Many probes, such as \[^11^C\]PIB[@bib27], [@bib28], \[^11^C\]SB-13[@bib29], [@bib30], \[^11^C\]AZD2184[@bib31], \[^18^F\]FPIB[@bib32], \[^18^F\]AZD4694[@bib33], [@bib34], \[^18^F\]FDDNP[@bib35], [@bib36], \[^18^F\]AV-1[@bib37], [@bib38], [@bib39], \[^18^F\]AV-45[@bib40], [@bib41], [@bib42] and \[^123^I\]IMPY[@bib20], have advanced in clinical trials. PET-based probes are more promising in terms of their translational applications. Three PET probes \[^18^F\]FPIB (Vizamyl^TM^), \[^18^F\]AV-45 (Amyvid^TM^) and \[^18^F\]AV-1 (Neuraceq^TM^) were recently approved by the FDA. The clinical diagnostic utility of these PET imaging agents is limited: they cannot be used to confirmatively diagnose AD, only to support other diagnostic criteria[@bib43]. Furthermore, the use of PET probes is limited by high cost and narrow availability, since generation of these probes needs specialized facilities that have a cyclotron for the generation of short-lived radionuclides (*e.g*., \[^11^C\], *t*~1/2~=20 min and \[^18^F\], *t*~1/2~=110 min) and an automated synthetic unit to produce radiolabelled probes. Compared with PET, SPECT has broader availability and lower cost as a routine diagnosis method due to the use of easily-generated radionuclides with longer half-lives (*e.g*., \[^125^I\], *t*~1/2~=60.1 d, \[^123^I\], *t*~1/2~=13.2 h, and \[^99m^Tc\], *t*~1/2~=6.0 h). Current SPECT-based probes either have relatively high background for the radioiodinated probes due to high lipophilicity and nonspecific binding or have poor blood-brain barrier (BBB) penetration in the case of ^99m^Tc-labeled SPECT probes. Only one SPECT probe, \[^123^I\]IMPY, has advanced in clinical trials. In general, radionuclear-based imaging modalities PET and SPECT are limited by high cost, radiation exposure, and single signal readout.

In contrast to the radionuclear-based imaging techniques, optical imaging modalities are rather inexpensive; important merits include nonradioactive, real-time imaging with the option of multi-targets tracing *in vitro* and *in vivo*, wide availability, and high-resolution imaging depending on the specific technique used[@bib44], [@bib45], [@bib46], [@bib47]. For *in vivo* applications, in order to avoid absorption and background autofluorescence and scattering of biological molecules, probe fluorescence emission wavelength in the near-infrared (NIR) region between 650 and 900 nm is advantageous so that one can achieve an optimal penetration depth and high sensitivity. Therefore, NIR fluorescence imaging has emerged as an attractive alternative to PET/SPECT and MRI techniques, and may provide a solution for the early diagnosis of AD. In the following sections, we discuss challenges and design strategies associated with the development of NIRF A*β* probes for *in vivo* applications, followed by a list of current reported probes and their optical, binding and brain-kinetic properties, as well as *in vitro* and/or *in vivo* studies ([Table 1](#t0005){ref-type="table"}).

2. Challenges in developing NIRF A*β* probes {#s0010}
============================================

A number of NIR fluorophores such as cyanine dyes (Cy7), indocyanine green dyes (ICG), alexa fluor dyes (660--790 nm), and SRfluor dyes have been developed and employed for *in vivo* applications; many of them are commercially available[@bib47]. Nonetheless, these known NIR fluorophores have large molecular weight and intrinsic charges. They are likely to be unsuitable for labeling A*β* plaques in the brain because of their limited BBB permeability. In order to use a fluorophore for *in vivo* brain A*β* imaging, several criteria are required[@bib48], [@bib49], [@bib50]: (1) a suitable wavelength of excitation and emission within the NIR range (650−900 nm); (2) high BBB permeability (log*P* values between 2 and 3.5, or *c*log*P*\<5.0 are considered optimal[@bib51], [@bib52]); (3) high affinity for specific labeling of the A*β* plaques in the brain with low nonspecific binding to other proteins; (4) rapid clearance of the unbound dye from the brain; and (5) significant changes in the probe fluorescence properties upon binding to A*β* plaques. It is challenging to design probes meeting all the requirements. First, many NIR fluorophores are often highly-conjugated structures with molecular weight over 600 Da, while a small and compact scaffold with molecular weight less than 600 Da is required for NIRF A*β* probes. Secondly, the probes should have balanced lipophilicity to ensure good BBB penetration and avoid nonspecific binding. Moreover, high affinity and significant fluorescence property changes require fluorophore scaffolds which are challenging to design. Ultimately, it is difficult to predict *in vivo* properties of a designed NIRF probe before synthesis and testing.

3. NIRF A*β* probes {#s0015}
===================

Compared with a vast number of PET/SPECT probes for A*β* plaques in the literature, there have been relatively few reports on the development of NIRF probes. This is no doubt due to the many challenges discussed in the previous section[@bib62]. In this section, we cover six different kinds of NIRF A*β* imaging probes in chronological order according to their publication dates. Their structures are shown in [Fig. 1](#f0005){ref-type="fig"}. Most of them are highly conjugated molecules containing the donor-acceptor or donor-acceptor-donor architecture. Their structural features are characterized by an electron-donating group linked to an electron-withdrawing group by an highly polarized conjugated *π-*electron chain, leading to non-linear optical properties, such as fluorescence intensity change in response to environmental change[@bib63]. Such architecture is particularly useful in the design of NIRF A*β* probes, since the recognition process often involves surrounding environmental changes of the probe[@bib48]. Moreover, physical, optical, and binding properties can be rationally tailored by varying the conjugated *π*-chain, the donor, and the acceptor groups[@bib48], [@bib60], [@bib61].

3.1. NIAD-4 and its analogs (NIAD-4, NIAD-11, and NIAD-16) {#s0020}
----------------------------------------------------------

In 2005, Swager et al.[@bib48] rationally designed the fluorescent probe NIAD-4 based upon the donor-*π*-bridge-acceptor architecture, which utilizes a highly polarizable bisthiophene to link the donor group (*p*-hydroxyphenyl) and the acceptor group (dicyanomethlyene). NIAD-4 showed excellent binding affinity (*K*~i~=10 nmol/L) for A*β* aggregates and a dramatic enhancement of the fluorescence intensity (about 400-fold) when mixing with A*β* aggregates. The increased fluorescence intensity was caused by reduced free rotation of aromatic rings in the excited state. *In vivo* two-photon imaging experiments in transgenic mice demonstrated NIAD-4 readily crossed the BBB after intravenous injection and labeled A*β* plaques in brain and cerebrovascular amyloid angiopathy on blood vessels ([Fig. 2](#f0010){ref-type="fig"})[@bib48]. In a separate study, NIAD-4 showed a broader pH tolerance than Thioflavin T in monitoring amyloid formation process, especially under acidic condition[@bib64]. NIAD-4 presented the first example of the rational design of A*β* specific probes to achieve emission wavelength over 600 nm upon binding with A*β* aggregates. However, the maximum emission wavelength of the probe NIAD-4 is only 603 nm, not in the optimal range of 650−900 nm. Studies with this probe required the use of the invasive cranial window technique to perform *in vivo* fluorescence imaging, which is impractical for clinical diagnosis[@bib48]. To achieve longer emissions, the same group subsequently developed a series of NIAD-4 analogs, including NIAD-11 and NIAD-16[@bib53], [@bib65]. NIAD-16 could distinguish vascular and nonvascular A*β* plaques from background signal through fluorescence lifetime imaging[@bib53].

3.2. AOI-987 {#s0025}
------------

In the same year, Gremlich et al.[@bib49] at Novartis designed and synthesized longer wavelength benzophenoxazine dyes, as NIRF probes for A*β* plaques. They could monitor the progression of A*β* deposition in APP23 transgenic mice, an animal model of AD. Among them, AOI-987 offered the best *in vivo* results. Although AOI-987 is a charged molecule and has only moderate affinity for A*β* aggregates (*K*~d~=220 nmol/L), the probe was able to penetrate the BBB and specifically label A*β* plaques as identified by *ex vivo* fluorescence imaging examination of brain slides ([Fig. 3](#f0015){ref-type="fig"}c). In addition, AOI-987 has an absorption and emission wavelength within the NIR range (650 and 670 nm, respectively) and a high quantum yield of 0.41. This fulfills the prerequisites for high sensitivity *in vivo* applications. *In vivo* time-dependent NIRF imaging experiments shown in [Fig. 3](#f0015){ref-type="fig"}b differentiated APP23 mice from wild type mice in as early as 9 months old. However, AOI-987 has the unfavorable properties of a small Stokes shift (25 nm) and marginal fluorescence changes upon mixing with A*β* aggregates. In addition, the clearance rate of AOI-987 in the brain is low and extended washout time (4 h) is needed to clearly differentiate specific and nonspecific binding *in vivo*[@bib49].

3.3. Curcumin derivatives (CRANAD-2, CRANAD-3, CRANAD-58, CRANAD-17, *etc.*) {#s0030}
----------------------------------------------------------------------------

To improve detection signals with noticeable fluorescence intensity alternation and a large Stokes shift, Moore and colleagues[@bib50] designed and synthesized a novel class of NIRF probes derived from curcumin structure. In the structure, a difluoroboronate moiety and two *p*-dimethyamino phenyl groups were integrated into the curcumin scaffold to form a donor-acceptor-donor architecture, significantly increasing the emission wavelength to 805 nm. In this series, CRANAD-2 showed high affinity (*K*~d~=38.7 nmol/L) and drastic fluorescence changes (70-fold fluorescence intensity increase, 90 nm hypochromic shift) upon binding to A*β* aggregates. Since bulky analogs CRANAD-6 and CRANAD-23 (structures not shown) did not show significant fluorescence change, it was assumed that the binding site of CRANAD-2 is stereo-hindered, likely to be the hydrophobic site containing the core fragment (KLVFF)[@bib56]. *In vitro* staining experiments revealed that CRANAD-2 was capable of selective detection of A*β* plaques in a brain section from a 12-month old APP-PS1 transgenic mouse ([Fig. 4](#f0020){ref-type="fig"}a). Notably, CRANAD-2 could differentiate Tg2576 mice from wild type at an early time point (30 min) after injection by comparison of fluorescence intensities in *in vivo* studies ([Fig. 4](#f0020){ref-type="fig"}b). CRANAD-2 meets most of the requirements as a NIRF A*β* probe *in vitro* and *in vivo*. Compared with PIB, a well-studied PET probe for A*β* plaques, CRANAD-2 has lower brain entrance/clearance rates[@bib50]. In another study reported by the same group, CRANAD-2 was used in combination with CRANAD-5 as a non-conjugated FRET pair for differentiating A*β* monomers from higher aggregated A*β* species including dimers[@bib66].

By replacing of benzene with pyridine and dimethylamino with diethylamino groups in CRANAD-2, with subsequent removal of the difluoroboron bridge, the same group reported another probe, CRANAD-3, in 2012. CRANAD-3 displayed significant fluorescence property changes upon binding to A*β* aggregates. What was different from CRANAD-2 was that it also interacted with soluble A*β* monomers and dimers, and displayed fluorescence signal change. *In vivo* imaging studies using transgenic APP/PS1 mice exhibited that CRANAD-3 could differentiate 2 month-old APP/PS1 mice from wild type mice. Furthermore, notably, CRANAD-3 could separate specific and nonspecific binding fluorescence signal of the probe in spectral unmixing imaging studies[@bib55].

More recently, new CRANAD-2 analogs were designed and synthesized aiming for NIRF imaging of soluble and insoluble A*β* species and inhibition of copper-ion induced A*β* aggregation[@bib56]. Among them, CRANAD-58 showed different fluorescence response towards soluble and insoluble A*β* species. Significant fluorescence intensity increase (91.9-fold for A*β*~40~, 113.6-fold for A*β*~42~) and high affinity (*K*~d~=105.8 nmol/L for A*β*~40~, 45.8 nmol/L for A*β*~42~) for A*β* monomers was observed. Similar fluorescent intensity changes were also seen with A*β* dimers, but to a lesser extent. *In vivo* experiments revealed that CRANAD-58 was able to detect soluble A*β* species in transgenic APP/PS1 mice at the age of 4 months. Another analog, CRANAD-17, containing two copper coordinating imidazoles, could compete and interfere with copper induced crosslinking of A*β*. CRANAD-17 induced 68% more of A*β* monomers as compared with non-treated samples in *in vitro* anti-crosslinking studies, indicating potential usage as theranostic agent[@bib56].

3.4. BODIPY based probes (BODIPY7, BAP-1 to BAP-5) {#s0035}
--------------------------------------------------

The high quantum yield, biocompatibility, and high lipophilicity of the BODIPY fluorophore render it attractive for the design of NIRF probes. In this regard, inspired by NIAD-4, Ono and his team[@bib57] reported their first BODIPY-derived fluorescence/SPECT dual probe BODIPY7. It contains a conjugated thiophene-phenyl chain similar to NIAD-4. BODIPY7 has modest affinity (*K*~i~=108 nmol/L) for A*β* aggregates and is able to detect A*β* plaques in *in vitro* staining of brain slides from an animal model of AD. The low BBB permeability, the short absorption/emission wavelength (606/613 nm), and the narrow Stokes shift restricts *in vivo* imaging applications[@bib57]. Two years later, the same group developed a new BODIPY-based A*β* imaging probe (BAP-1) with a \"privileged" *p*-dimethylamino phenyl group to improve *in vivo* properties. BAP-1 showed high affinity (*K*~d~=44.1 nmol/L) and a significant fluorescence intensity increase upon binding to A*β* aggregates. It also has exceptional brain kinetic profiles and demonstrated specific labeling of A*β* plaques based on *in vitro* and *ex vivo* staining studies ([Fig. 5](#f0025){ref-type="fig"}). Nonetheless, it failed in *in vivo* imaging experiments using Tg2576 mice as the disease model, mainly due to unfavorable nonspecific binding in the scalp. Furthermore, the emission wavelength of BAP-1 (648 nm) was still short for *in vivo* imaging[@bib58]. In 2013, several BAP-1 analogs (BAP-2, BAP-3, BAP-4, and BAP-5) with emission wavelength over 700 nm were disclosed. Similar to BAP-1, they were able to selectively label A*β* plaques *in vitro* and *ex vivo*. The probe, BAP-2, was selected for *in vivo* imaging but failed due to the same problem of higher accumulation in the scalp than in the brain, potentially related to high lipophilicity of the BODIPY group[@bib59]. These studies reveal the issues associated with BODIPY-based probes, including narrow Stokes shifts causing potential interference from Raman and Rayleigh scattering, and high lipophilicity leading to nonspecific binding and high background in lipid membranes.

3.5. THK-265 {#s0040}
------------

Inspired by the reported studies, Okamura and colleagues[@bib54] screened a collection of simple conjugated compounds, which led to the new NIRF A*β* probe, THK-265. This probe possess an emission wavelength around 650 nm combined with favorable physical properties such as high quantum yield, high molar absorption coefficients, and moderate log*P* value. A high binding affinity (*K*~d~=97 nmol/L) and 6-fold fluorescence intensity increase upon mixing with A*β*~42~ fibrils were observed, albeit no significant change in emission wavelength. THK-265 was further evaluated for its *in vivo* imaging performance using A*β*PP transgenic mice. Such studies demonstrated that this probe crossed the BBB and selectively labeled A*β* plaques in the brain following intravenous administration. Compared with AOI-987 under the same experimental conditions, THK-265 showed an earlier differentiation time and better imaging contrast between transgenic mice and wild type and higher sensitivity for plaque detection *in vivo*. Most importantly, the fluorescence intensity of THK-265 correlated well with A*β* plaque burden, indicating its potential in monitoring progression of the A*β* aggregation in AD[@bib54]. Subsequently, Schmidt and Pahnke[@bib67] demonstrated that indeed THK-265 could be used for direct monitoring and evaluating different cerebral A*β* aggregation levels in different stage of AD progression in an animal AD model.

3.6. DANIR 2c and its analogs (MAAD-3, DMDAD-3, MCAAD-3,and DMMAD-3) {#s0045}
--------------------------------------------------------------------

Earlier experiences from previous studies of the BODIPY series of NIRF A*β* probes led to the design of improved ones. By replacement of the undesired BODIPY with simple conjugated systems, Ono and Cui et al.[@bib60] designed and synthesized a new series of structurally simplified A*β* fluorescent probes DANIRs. The *p*-dimethylamino phenyl moiety was used as the donor group on one side of polymethine, with dicyanomethylene as the acceptor on the other end. This design significantly reduced molecular weights of the probes and improved brain kinetics. The best probe in the series, DANIR 2c, was able to efficiently cross the BBB and label A*β* plaques ([Fig. 6](#f0030){ref-type="fig"}a) with a fast washout rate of the unbound probe. This probe differentiated between Tg mice and wild type as early as 30 min after *in vivo* administration of the probe ([Fig. 6](#f0030){ref-type="fig"}b), a significantly shorter time as compared with that from AOI-987. DANIR 2c also has favorable optical properties (emission wavelength at 665 nm), a 12-fold increase in intensity upon mixing with A*β* aggregates, and excellent affinity for A*β* aggregates (*K*~i~=37 nmol/L, *K*~d~=27 nmol/L). DANIR 2c meets most of the requirements as an optimal probe for *in vivo* imaging of A*β* plaques[@bib60]. One shortcoming is the blue-shift of this probe's emission wavelength to only 625 nm (shorter than 650 nm) following binding to A*β* plaques.

Encouraged by the excellent performance of DANIR 2c, Cui et al.[@bib61] then turned to its analogs for better NIRF probes with longer emission wavelength. Four analogs MAAD-3, DMDAD-3, MCAAD-3, and DMMAD-3 were synthesized, by differing in the donor group. These analogs showed extended emission wavelength and significant reduced binding affinity to A*β* aggregates compared with DANIR 2c. Docking simulations suggested that these probes likely bind to the same binding site as IMPY, which was a thin hydrophobic groove parallel to the fibrillar axis formed by VAL 18 and PHE 20. Increased bulkiness of the acceptor group within these analogs caused a reduced binding efficiency. One analog, MCAAD-3, which had the highest affinity of 106 nmol/L among the series, was selected for *in vivo* imaging studies. Similar to DANIR 2c, MCAAD-3 exhibited good brain kinetics, including rapid initial uptake and fast egress. Furthermore, the latter could differentiate Tg from wild type mice at the earliest point of 30 min after dosing as well. Overall, MCAAD-3 may be a better NIRF probe for *in vivo* imaging than DANIR 2c, as the emission wavelength was at 654 nm when bound to A*β* aggregates.

4. Conclusions {#s0050}
==============

This review highlights the development of NIRF imaging probes for *in vivo* detection of A*β* plaques in the past ten years. Six structurally distinct NIRF fluorophore scaffolds of A*β* probes have been developed. Most of these probes present high affinity for A*β in vitro*. As for *in vivo* imaging applications, pharmacokinetics-related properties are as vital as optical properties. Such pharmacokinetics considerations include *in vivo* stability, low-affinity for serum albumin, and reasonable lipophilicity, all of which are required for fast initial uptake into brain and fast washout to reduce nonspecific binding. In addition, significant fluorescence signal changes upon binding to A*β* are required. Other considerations regarding optical properties include absorption/excitation/emission in NIR region, high molar absorption coefficient, high quantum yield, and longer Stokes shifts. The currently reported probes fell short on one or several aspects of these required properties. NIAD-4 and DANIR 2c display a short emission wavelength, but charged AOI-987 is difficult to penetrate the BBB. CRANAD-2 has a slow egress, and BODIPYs suffer from a short Stokes shift and nonspecific binding in the scalp. Marginal fluorescent signal changes are observed with THK-265 upon binding to A*β* aggregates. MCAAD-3 has a relatively lower binding affinity than that of NIAD-4 or DANIR 2c.

Despite these concerns, development of these probes demonstrate the feasibility of NIRF imaging using A*β* specific fluorescence probes as a low-cost, convenient, readily available, and real-time approach for early diagnosis of AD in mice AD models. We believe that, in the future, the NIRF A*β* probes with enhanced pharmacokinetics and optical properties will be great benefits to human health through improved early AD diagnosis, evaluation of disease progression and clinical therapeutic outcomes.
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![Structures of NIR fluorescence probes covered in this review (donor and acceptor groups were labeled in blue and red, respectively). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}

![(a) *In vitro* staining of A*β* deposits with NIAD-4 in a coronal section of a transgenic mouse brain. Scale bar, 1 mm. (b) *In vivo* two-photon fluorescent image of A*β* plaques and cerebrovascular amyloid angiopathy. Scale bar, 30 μm. (Adapted with permission from Ref.[@bib48]. Copyright 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)](gr2){#f0010}

![(a) *In vitro* staining of A*β* plaques with AOI-987 in a transgenic mouse brain section \[scale bars, 1 mm (large panel) and 100 μm (lower panels)\]. (b) *In vivo* images of female 17-month-old APP23 transgenic (top row) and wild-type (middle row) mice at different time points (30, 60, 120, 240 min) after injected *i.v.* with 0.1 mg/kg AOI-987, and corresponding images of a female 17-month-old transgenic APP23 mouse treated with 0.9% saline (bottom row) (scale bar, 1 cm; color scale bars in arbitrary units). (c) *Ex vivo* NIRF image of a brain section (20 μm thickness) of 16-month-old female transgenic mouse administrated with 0.1 mg/kg AOI-987 (scale bar, 100 μmol/L). (Adapted with permission from Ref.[@bib49]. Copyright 2005 Macmillan Publishers Ltd.: Nature Biotechnology.)](gr3){#f0015}

![(a) *In vitro* staining of A*β* plaques with CRANAD-2 in a twelve old APP-PS1 transgenic mouse brain section (magnification: left, 2×; middle, 10×; right, 40×). (b) *In vivo* images of female 19-month-old wild type (top row) and Tg2576 (bottom row) mice at different time points (30, 60, 120, 240 min) after injected *i.v.* with 5.0 mg/kg CRANAD-2. (Adapted with permission from Ref.[@bib50]. Copyright 2009 American Chemical Society.)](gr4){#f0020}

![(a) *In vitro* staining of A*β* plaques with BAP-1 in a Tg2576 mouse brain section *versus* a wild-type mouse brain section. (b) Comparison of the *ex vivo* fluorescence intensity in the brain of a 25-month-old Tg2576 and age-matched wild-type mice 1 h after intravenous administration of BAP-1. (Adapted with permission from Ref.[@bib58]. Copyright 2012 American Chemical Society.)](gr5){#f0025}

![(a) *Ex vivo* image of A*β* plaques in a Tg mouse brain section treated with intravenous administration of 0.4 mg/kg DANIR 2c. (b) *In vivo* images of female 22-month-old wild type (top row) and APPsw/PSEN1 transgenic (bottom row) mice at different time points (2, 10, 30, 60 min) after injected with 0.4 mg/kg DANIR 2c. (Adapted with permission from Ref.[@bib60]. Copyright 2014 American Chemical Society.)](gr6){#f0030}

###### 

Summary of NIR imaging probes for A*β* plaques.

  Name        M. W.    *K*~i~ (nmol/L)   *K*~d~ (nmol/L)   *c*log*P*[a](#tbl1fna){ref-type="table-fn"} (log*P*[b](#tbl1fnb){ref-type="table-fn"})   *ε* (M^−1^ cm^−1^)                        *λ*~abs~ (nm)                           *λ*~ex~ (nm)                            *λ*~em~ (nm) (free)                     *λ*~em~ (nm) (binding)                                                        *Φ* (%)                                                                                                                                                     Intensity incresement (fold)                                                 References
  ----------- -------- ----------------- ----------------- ---------------------------------------------------------------------------------------- ----------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------
  NIAD-4      334.41   10                --                4.52                                                                                     35700[c](#tbl1fnc){ref-type="table-fn"}   --                                      492[c](#tbl1fnc){ref-type="table-fn"}   603[c](#tbl1fnc){ref-type="table-fn"}   --                                                                            0.008[d](#tbl1fnd){ref-type="table-fn"}, 5[e](#tbl1fne){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}                                           400[f](#tbl1fnf){ref-type="table-fn"}                                        [@bib48]
  NIAD-11     400.47   --                --                4.77                                                                                     --                                        545[g](#tbl1fng){ref-type="table-fn"}   --                                      690[g](#tbl1fng){ref-type="table-fn"}   \~710[f](#tbl1fnf){ref-type="table-fn"}                                       11[e](#tbl1fne){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}                                                                                   --                                                                           [@bib53]
  NIAD-16     361.48   --                --                5.33                                                                                     --                                        470[g](#tbl1fng){ref-type="table-fn"}   --                                      720[g](#tbl1fng){ref-type="table-fn"}   --                                                                            --                                                                                                                                                          --                                                                           [@bib53]
  AOI-987     324.35   --                220               1.66                                                                                     61930[i](#tbl1fni){ref-type="table-fn"}   650[i](#tbl1fni){ref-type="table-fn"}   --                                      670[i](#tbl1fni){ref-type="table-fn"}   --                                                                            41[i](#tbl1fni){ref-type="table-fn"}                                                                                                                        --                                                                           [@bib49]
  THK-265     350.37   --                97                −0.29 (1.8)                                                                              96198[c](#tbl1fnc){ref-type="table-fn"}   --                                      627[c](#tbl1fnc){ref-type="table-fn"}   644[c](#tbl1fnc){ref-type="table-fn"}   650                                                                           38.5[c](#tbl1fnc){ref-type="table-fn"}                                                                                                                      3.6[f](#tbl1fnf){ref-type="table-fn"}, 6[h](#tbl1fnh){ref-type="table-fn"}   [@bib54]
  CRANAD-2    410.26   --                38.7              5.56 (3.0)                                                                               --                                        --                                      640[g](#tbl1fng){ref-type="table-fn"}   805[g](#tbl1fng){ref-type="table-fn"}   715                                                                           0.6[d](#tbl1fnd){ref-type="table-fn"},40[e](#tbl1fne){ref-type="table-fn"}^,^[f](#tbl1fnf){ref-type="table-fn"}                                             70[c](#tbl1fnc){ref-type="table-fn"}                                         [@bib50]
  CRANAD-3    420.55   --                --                5.13                                                                                     --                                        --                                      --                                      700[g](#tbl1fng){ref-type="table-fn"}   640[g](#tbl1fng){ref-type="table-fn"}                                         --                                                                                                                                                          --                                                                           [@bib55]
  CRANAD-58   439.31   --                --                5.67 (1.94)                                                                              --                                        --                                      \~630                                   \~750                                   \~700[f](#tbl1fnf){ref-type="table-fn"}                                       --                                                                                                                                                          --                                                                           [@bib56]
  CRANAD-17   456.25   --                --                5.11                                                                                     --                                        --                                      --                                      \~600                                   \~560[f](#tbl1fnf){ref-type="table-fn"}                                       --                                                                                                                                                          --                                                                           [@bib56]
  BODIPY7     530.18   108               --                9.08 (2.2)                                                                               --                                        606                                     --                                      613                                     --                                                                            36                                                                                                                                                          --                                                                           [@bib57]
  BAP-1       351.20   --                44.1              5.47                                                                                     --                                        604[j](#tbl1fnj){ref-type="table-fn"}   614[j](#tbl1fnj){ref-type="table-fn"}   648[j](#tbl1fnj){ref-type="table-fn"}   --                                                                            46.8[j](#tbl1fnj){ref-type="table-fn"}                                                                                                                      --                                                                           [@bib58]
  BAP-2       357.23   --                54.6              5.24                                                                                     --                                        651[j](#tbl1fnj){ref-type="table-fn"}   650[j](#tbl1fnj){ref-type="table-fn"}   708[j](#tbl1fnj){ref-type="table-fn"}   --                                                                            11.4[j](#tbl1fnj){ref-type="table-fn"}                                                                                                                      --                                                                           [@bib59]
  BAP-3       341.16   --                149               4.65                                                                                     --                                        665[j](#tbl1fnj){ref-type="table-fn"}   663[j](#tbl1fnj){ref-type="table-fn"}   705[j](#tbl1fnj){ref-type="table-fn"}   --                                                                            4.5[j](#tbl1fnj){ref-type="table-fn"}                                                                                                                       --                                                                           [@bib59]
  BAP-4       433.32   --                26.8              7.24                                                                                     --                                        623[j](#tbl1fnj){ref-type="table-fn"}   636[j](#tbl1fnj){ref-type="table-fn"}   704[j](#tbl1fnj){ref-type="table-fn"}   --                                                                            9.3[j](#tbl1fnj){ref-type="table-fn"}                                                                                                                       --                                                                           [@bib59]
  BAP-5       417.26   --                18.1              6.75                                                                                     --                                        639[j](#tbl1fnj){ref-type="table-fn"}   649[j](#tbl1fnj){ref-type="table-fn"}   723[j](#tbl1fnj){ref-type="table-fn"}   --                                                                            4.3[j](#tbl1fnj){ref-type="table-fn"}                                                                                                                       --                                                                           [@bib59]
  DANIR 2c    249.31   37                27                2.81                                                                                     50119[k](#tbl1fnk){ref-type="table-fn"}   519[k](#tbl1fnk){ref-type="table-fn"}   597[g](#tbl1fng){ref-type="table-fn"}   665[g](#tbl1fng){ref-type="table-fn"}   625[h](#tbl1fnh){ref-type="table-fn"}                                         4.09[k](#tbl1fnk){ref-type="table-fn"}                                                                                                                      12[h](#tbl1fnh){ref-type="table-fn"}                                         [@bib60]
  MAAD-3      327.37   354               --                4.28                                                                                     --                                        --                                      --                                      704[g](#tbl1fng){ref-type="table-fn"}   674 [g](#tbl1fng){ref-type="table-fn"}^,^[h](#tbl1fnh){ref-type="table-fn"}   4.71 [d](#tbl1fnd){ref-type="table-fn"}^,^[k](#tbl1fnk){ref-type="table-fn"} 0.048[d](#tbl1fnd){ref-type="table-fn"}^,^[g](#tbl1fng){ref-type="table-fn"}   15[h](#tbl1fnh){ref-type="table-fn"}                                         [@bib61]
  DMDAD-3     323.43   645               --                4.36                                                                                     --                                        --                                      --                                      725[g](#tbl1fng){ref-type="table-fn"}   694 [g](#tbl1fng){ref-type="table-fn"}^,^[h](#tbl1fnh){ref-type="table-fn"}   2.68 [d](#tbl1fnd){ref-type="table-fn"}^,^[k](#tbl1fnk){ref-type="table-fn"} 0.033[d](#tbl1fnd){ref-type="table-fn"}^,^[g](#tbl1fng){ref-type="table-fn"}   7[h](#tbl1fnh){ref-type="table-fn"}                                          [@bib61]
  MCAAD-3     282.34   106               --                3.16                                                                                     --                                        --                                      --                                      685[g](#tbl1fng){ref-type="table-fn"}   654 [g](#tbl1fng){ref-type="table-fn"}^,^[h](#tbl1fnh){ref-type="table-fn"}   1.23[d](#tbl1fnd){ref-type="table-fn"}^,^[k](#tbl1fnk){ref-type="table-fn"} 0.250[d](#tbl1fnd){ref-type="table-fn"}^,^[g](#tbl1fng){ref-type="table-fn"}    26[h](#tbl1fnh){ref-type="table-fn"}                                         [@bib61]
  DMMAD-3     315.36   652               --                3.53                                                                                     --                                        --                                      --                                      687[g](#tbl1fng){ref-type="table-fn"}   642 [g](#tbl1fng){ref-type="table-fn"}^,^[h](#tbl1fnh){ref-type="table-fn"}   0.10 [d](#tbl1fnd){ref-type="table-fn"}^,^[k](#tbl1fnk){ref-type="table-fn"} 0.068[d](#tbl1fnd){ref-type="table-fn"}^,^[g](#tbl1fng){ref-type="table-fn"}   8[h](#tbl1fnh){ref-type="table-fn"}                                          [@bib61]

Calculated using ChemBioDraw 12.0 software.

Experimental value.

Measured in methanol.

Quantum yield before binding.

Quantum yield after binding to A*β* fibrils/aggregates.

For A*β*~40~ fibrils/aggregates.

Measured in PBS.

For A*β*~42~ fibrils/aggregates.

Measured in serum.

Measured in chloroform.

Measured in dichloromethane.
